Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.

MLA

Clavarezza, Matteo, et al. “Phase II Open-Label Study of Bevacizumab Combined with Neoadjuvant Anthracycline and Taxane Therapy for Locally Advanced Breast Cancer.” Breast (Edinburgh, Scotland), vol. 22, no. 4, Aug. 2013, pp. 470–75. EBSCOhost, https://doi.org/10.1016/j.breast.2013.03.012.

APA

Clavarezza, M., Turazza, M., Aitini, E., Saracchini, S., Garrone, O., Durando, A., De Placido, S., Bisagni, G., Levaggi, A., Bighin, C., Restuccia, E., Scalamogna, R., Galli, A., & Del Mastro, L. (2013). Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer. Breast (Edinburgh, Scotland), 22(4), 470–475. https://doi.org/10.1016/j.breast.2013.03.012

Chicago

Clavarezza, Matteo, Monica Turazza, Enrico Aitini, Silvana Saracchini, Ornella Garrone, Antonio Durando, Sabino De Placido, et al. 2013. “Phase II Open-Label Study of Bevacizumab Combined with Neoadjuvant Anthracycline and Taxane Therapy for Locally Advanced Breast Cancer.” Breast (Edinburgh, Scotland) 22 (4): 470–75. doi:10.1016/j.breast.2013.03.012.